

Published in final edited form as:

Science. 2010 December 3; 330(6009): 1410–1413. doi:10.1126/science.1194472.

Frequent Mutation of *BAP1* in Metastasizing Uveal Melanomas

J. William Harbour^{1,3,*}, Michael D. Onken¹, Elisha D.O. Roberson², Shenghui Duan², Li Cao², Lori A. Worley¹, M. Laurin Council², Katie A. Matatall¹, Cynthia Helms², and Anne M. Bowcock^{2,3,*}

¹Department of Ophthalmology & Visual Sciences, Washington University School of Medicine, St. Louis, MO, 63110, U.S.A

²Department of Genetics, Washington University School of Medicine, St. Louis, MO, 63110, U.S.A

³Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, 63110, U.S.A

Abstract

Metastasis is a defining feature of malignant tumors and is the most common cause of cancer-related death, yet the genetics of metastasis are poorly understood. We used massively parallel exome sequencing coupled with Sanger re-sequencing to search for metastasis-related mutations in highly metastatic uveal melanomas of the eye. Inactivating somatic mutations were identified in the gene encoding BRCA1-associated protein 1 (*BAP1*) on chromosome 3p21.1 in 26 of 31 (84%) metastasizing tumors, including 15 mutations causing premature protein termination, and six affecting its ubiquitin carboxy-terminal hydrolase (UCH) domains. One tumor harbored a frameshift mutation that was germline in origin, thus representing a susceptibility allele. These findings implicate loss of *BAP1* in uveal melanoma metastasis and suggest the *BAP1* pathway as a therapeutic target.

Uveal melanoma (UM) is the most common primary cancer of the eye and has a strong propensity for fatal metastasis (1). UMs are divided into class 1 (low metastatic risk) and class 2 (high metastatic risk) based on a validated multi-gene clinical prognostic assay included in the TNM classification system (2, 3). However, the genetic basis of metastasis remains unclear. Oncogenic mutations in the $G\alpha_q$ stimulatory subunit *GNAQ* are common in UM (4), but these mutations occur early in tumorigenesis and are not correlated with molecular class or metastasis (5, 6). On the other hand, class 2 tumors are strongly associated with monosomy 3 (7), suggesting that loss of one copy of chromosome 3 may unmask a mutant gene on the remaining copy which promotes metastasis.

Using exome capture followed by massively parallel sequencing (8-10), we analyzed two class 2 tumors that were monosomic for chromosome 3 (MM56 and MM70) and matching normal DNA from peripheral blood lymphocytes. Both tumors contained inactivating mutations in *BAP1*, located at chromosome 3p21.1 (Fig. 1A) (10). MM56 contained a C/G to T/A transition that created a premature termination codon (p.W196X). MM70 contained a

*To whom correspondence should be addressed: A.M.B. (bowcock@genetics.wustl.edu) or J.W.H. (harbour@vision.wustl.edu).

Supporting Online Material

- Materials and Methods
- Figs. S1 to S5
- Tables S1 to S3
- References

deletion of 11bp in exon 11, leading to a frameshift and premature termination of the *BAP1* protein (p.Q322fsX100). The matched normal DNA samples did not contain these mutations, indicating that they were likely to be somatic in origin. No gene on chromosome 3 other than *BAP1* contained deleterious somatic mutations that were present in both tumors (table S3).

BAP1 encodes a nuclear ubiquitin carboxy-terminal hydrolase (UCH), one of several classes of deubiquitinating enzymes (11). In addition to the UCH catalytic domain, *BAP1* contains a UCH37-like domain (ULD) (12), binding domains for BRCA1 and BARD1, which form a tumor suppressor heterodimeric complex (13), and a binding domain for HCFC1, which interacts with histone-modifying complexes during cell division (12, 14, 15). *BAP1* also interacts with ASXL1 to form the Polycomb group repressive deubiquitinase complex (PR-DUB), which is involved in stem cell pluripotency and other developmental processes (16, 17). *BAP1* exhibits tumor suppressor activity in cancer cells (11, 13), and *BAP1* mutations have been reported in a small number of breast and lung cancer samples (11, 18).

To further investigate *BAP1*, genomic DNA from 29 additional class 2 UMs, and 26 class 1 UMs were subjected to Sanger re-sequencing of all *BAP1* exons. Altogether, *BAP1* mutations were identified in 26 of 31 (84%) class 2 tumors, including 13 out-of-frame deletions and two nonsense mutation leading to premature protein termination, six missense mutations, four in-frame deletions, and one mutation predicted to produce an abnormally extended *BAP1* polypeptide (Fig. 1A-C) (10). Three of the missense mutations affected catalytic residues of the UCH active site (C91 and H169), two occurred elsewhere in the UCH domain, and one affected the ULD (Fig. 1B-C). All *BAP1* missense mutations and in-frame deletions affected phylogenetically conserved amino acids (fig. S1). Only one of 26 class 1 tumors contained a *BAP1* mutation (NB101) (10). This case may represent a transition state in which the tumor has sustained a *BAP1* mutation but has not yet converted to class 2, suggesting that *BAP1* mutations may precede the emergence of the class 2 signature. Somatic *BAP1* mutations were also detected in two of three metastatic tumors (10).

One copy of chromosome 3 was missing in all 17 *BAP1*-mutant class 2 tumors for which cytogenetic data were available, consistent with chromosome 3 loss uncovering recessive *BAP1* mutations (10). Normal DNA from 20 patients with *BAP1*-mutant class 2 primary tumors and the two with metastatic tumors was available and did not contain a *BAP1* mutation, indicating that the mutations were somatic in origin. However, we detected one germline mutation (p.E402fsX2; c.1318-1319insA) in the patient with tumor MM 087 (table S2) suggesting that germline alterations in *BAP1* can predispose to UM. *GNAQ* mutation status was available in 15 cases. *GNAQ* mutations were present in 4/9 *BAP1* mutant tumors and 3/6 *BAP1* wildtype tumors, indicating that there was no correlation between *GNAQ* and *BAP1* mutation status.

Quantitative RT-PCR showed that *BAP1* mRNA levels were significantly lower in class 2 tumors compared to class 1 tumors ($P < 0.0001$) (Fig. 1D). Truncating mutations were associated with significantly lower mRNA levels than missense mutations ($P = 0.001$) (Fig. 1E), consistent with nonsense mediated mRNA decay in the former group. Class 2 tumors in which *BAP1* mutations were not identified expressed very low levels of *BAP1* mRNA (Fig. 1E).

To determine whether the low *BAP1* mRNA levels in class 2 tumors without detectable *BAP1* mutations may be explained by DNA methylation, we performed a preliminary analysis of DNA methylation of *BAP1*. This did not reveal a convincing difference between class 1 and class 2 tumors (10). However, analysis of the *BAP1* promoter was limited by an

unusually complex CpG island that will require further work to resolve. Thus, we cannot rule out a role for methylation in class 2 tumors in which BAP1 mutations were not found. However, with almost 85% of class 2 tumors harboring mutations, we do not expect that methylation will be a major mechanism of BAP1 inactivation. An alternative explanation is that these tumors may contain very large deletions of the *BAP1* locus not detectable by our sequencing method.

Immunofluorescence revealed abundant nuclear BAP1 protein in two class 1 tumors but virtually none in four *BAP1* mutant class 2 tumors (fig. S3). This was expected for the two tumors with mutations expected to cause premature protein terminations (MM 091 and MM 100), but it was surprising for the two tumors with missense mutations (MM 071 and MM 135) and suggests that these mutations lead to protein instability.

RNAi-mediated knock down of BAP1 in 92.1 UM cells, which did not harbor a detectable *BAP1* mutation, recapitulated many characteristics of the de-differentiated class 2 UM phenotype (19). Cells transfected with control siRNA exhibited typical melanocytic morphology, including dendritic projections and cytoplasmic melanosomes (Fig. 2A), whereas cells transfected with BAP1 siRNA lost these features, developed a rounded epithelioid morphology and grew as multicellular non-adherent spheroids, strikingly similar to the features of class 2 clinical biopsy samples (Fig. 2A). Microarray gene expression profiling of 92.1 UM cells transfected with control versus BAP1 siRNA showed that most of the top genes that discriminate between class 1 and class 2 tumors shifted in the class 2 direction in BAP1 depleted cells compared to control cells (fig. S4). Similarly, depletion of BAP1 shifted the gene expression profile of the multi- gene clinical prognostic assay towards the class 2 signature (Fig. 2B). BAP1 depletion caused a reduction in mRNA levels of neural crest migration genes (*ROBO1*), melanocyte differentiation genes (*CTNNB1*, *EDNRB* and *SOX10*) and other genes that are down-regulated in class 2 tumors (*LMCD1* and *LTA4H*) (19). In contrast, BAP1 depletion caused an increase in mRNA levels of *CDH1* and the proto-oncogene *KIT*, which are highly expressed in class 2 tumors (20). Similar results were seen in other UM cell lines and with an independent BAP1 siRNA (10).

GNAQ mutations occur early in UM and are not sufficient for malignant transformation (4), but they may create a dependency of the tumor cells on constitutive *GNAQ* activity. In contrast, *BAP1* mutations occur later in UM progression and coincide with the onset of metastatic behavior. Thus, simultaneous targeting of both genetic alterations might have synergistic therapeutic effects. One potential strategy to counteract the effects of BAP1 mutation would be to inhibit the RING1 ubiquitinating activity that normally opposes the deubiquitinating activity BAP1 (16). Our findings strongly implicate mutational inactivation of *BAP1* as a key event in the acquisition of metastatic competence in UM, and they dramatically expand the role of BAP1 and other deubiquitinating enzymes as potential therapeutic targets in cancer.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

Supported by grants to J.W.H. from the National Cancer Institute (R01 CA125970), Barnes-Jewish Hospital Foundation, Kling Family Foundation, Tumori Foundation, Horncrest Foundation, and a Research to Prevent Blindness David F. Weeks Professorship, and by awards to the Department of Ophthalmology and Visual Sciences at Washington University from a Research to Prevent Blindness, Inc. Unrestricted grant, and the NIH Vision Core Grant P30 EY02687c. E.D.O.R. was supported by NIH/NIAMS training grant AR007279-31A1. We thank Jess Hoisington-Lopez from the Center for Genome Sciences (Wash Univ. School of Medicine) for running Solexa

paired end sequences, and Dr. Michael Lovett for comments on the manuscript. J.W.H. and Washington University may receive income based on a license of related technology by the University to Castle Biosciences, Inc.

References and Notes

1. Landreville S, Agapova OA, Harbour JW. *Future Oncol.* 2008; 4:629. [PubMed: 18922120]
2. Onken MD, Worley LA, Tuscan MD, Harbour JW. *J Mol Diagn.* 2010; 12:461. [PubMed: 20413675]
3. Finger PT. *Arch Pathol Lab Med.* 2009; 133:1197. [PubMed: 19653708]
4. Van Raamsdonk CD, et al. *Nature.* 2009; 457:599. [PubMed: 19078957]
5. Onken MD, et al. *Invest Ophthalmol Vis Sci.* 2008; 49:5230. [PubMed: 18719078]
6. Bauer J, et al. *Br J Cancer.* 2009; 101:813. [PubMed: 19654573]
7. Worley LA, et al. *Clin Cancer Res.* 2007; 13:1466. [PubMed: 17332290]
8. Bashardes S, et al. *Nat Methods.* 2005; 2:63. [PubMed: 16152676]
9. Ng SB, et al. *Nat Genet.* 2010; 42:30. [PubMed: 19915526]
10. See supporting material on Science Online
11. Jensen DE, et al. *Oncogene.* 1998; 16:1097. [PubMed: 9528852]
12. Misaghi S, et al. *Mol Cell Biol.* 2009; 29:2181. [PubMed: 19188440]
13. Nishikawa H, et al. *Cancer Res.* 2009; 69:111. [PubMed: 19117993]
14. Machida YJ, Machida Y, Vashisht AA, Wohlschlegel JA, Dutta A. *J Biol Chem.* 2009; 284:34179. [PubMed: 19815555]
15. Tyagi S, Chabes AL, Wysocka J, Herr W. *Mol Cell.* 2007; 27:107. [PubMed: 17612494]
16. Gaytan de Ayala Alonso A, et al. *Genetics.* 2007; 176:2099. [PubMed: 17717194]
17. Scheuermann JC, et al. *Nature.* 2010; 465:243. [PubMed: 20436459]
18. Wood LD, et al. *Science.* 2007; 318:1108. [PubMed: 17932254]
19. Onken MD, et al. *Cancer Res.* 2006; 66:4602. [PubMed: 16651410]
20. Onken MD, Worley LA, Ehlers JP, Harbour JW. *Cancer Res.* 2004; 64:7205. [PubMed: 15492234]
21. Misaghi S, et al. *Journal of Biological Chemistry.* 2005; 280:1512. [PubMed: 15531586]
22. Wang Y, et al. *Nucleic Acids Res.* 2007; 35:D298. [PubMed: 17135201]




Fig. 1.

Inactivating mutations in *BAP1* occur frequently in uveal melanomas. **(A)** Sanger sequence traces of MM 056 and MM 070 at the sites of the mutations. Location of mutated base in MM 056 and the start of the deletion of MM 070 are indicated (arrows). The non-coding *BAP1* strand is shown for MM 070. **(B)** Map of *BAP1* gene and location of *BAP1* mutations. *BAP1* contains 17 exons (shaded boxes) that encode a 728 amino acid protein. Introns are not to scale. Mutations are shown below the gene figure as indicated. The UCH domain (aa. 1-188) and UCH37-like domain (ULD) (aa. 635-693) are indicated (12, 13). The critical Q, C, H and D residues of the active site (Gln85, Cys91, His169 and Asp184) are indicated with asterisks. The catalytic cysteine is indicated with a circle. Also shown are: the NHNY consensus sequence for interaction with HCFC1 (aa. 363-365, exon 11), nuclear localization signals (NLS) at aa. 656-661 (exon 15) and aa. 717-722 (exon 17), the BARD1 binding domain within the region bounded by aa. 182-240 (13), and the BRCA1 binding domain within aa. 598-729 (11). **(C)** Location of *BAP1* missense mutations in the UCH domain aligned to the crystal structure of *UCH-L3* (21). Three-dimensional structure of *UCH-L3* was visualized with MMDB software (22). The small molecule near C91G, H169Q and S172R represents a suicide inhibitor, illustrating the critical location of these mutations for catalytic activity. **(D)** *BAP1* mRNA levels measured by quantitative RT-PCR in 9 non-metastasizing class 1 UMs and 28 metastasizing class 2 UMs. **(E)** Relationship between *BAP1* mRNA levels (measured by quantitative RT-PCR) and type of *BAP1* mutation in 9 UMs with nonsense mutations, 10 UMs with missense mutations (including small in-frame deletions, splice acceptor, and stop codon read-through mutations), and 4 class 2 UMs in which no *BAP1* mutations were detected.




Fig. 2. UM cells depleted of BAP1 acquire properties that are typical of metastasizing class 2 tumor cells. **(A)** Phase contrast photomicrographs of 92.1 uveal melanoma cells transfected with BAP1 or control siRNA at the indicated days. Bottom panels show representative examples of class 1 and class 2 uveal melanoma cells obtained from patient biopsy samples (Papanicolaou stain). Scale bars, 10 microns. **(B)** 92.1 cells transfected with BAP1 siRNA and evaluated after five days. BAP1 protein levels were efficiently depleted to less than 95% of control levels (see western blot). Upper panel depicts principal component analysis to show effect of BAP1 knockdown on gene expression signature. The small spheres represent the training set of known class 1 (blue) and class 2 (red) tumors. Large spheres represent the control-transfected (gray) and BAP1 siRNA transfected (red) cells. Lower panel depicts mRNA levels measured by quantitative RT-PCR of a panel of melanocyte lineage genes, presented as fold change in BAP1 siRNA/control siRNA transfected cells. Results are representative of three independent experiments.